19-4816148-A-C
Position:
Variant summary
Our verdict is Benign. Variant got -14 ACMG points: 0P and 14B. BP4_StrongBP6_ModerateBA1
The NM_182919.4(TICAM1):c.*91T>G variant causes a 3 prime UTR change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.253 in 1,388,318 control chromosomes in the GnomAD database, including 45,987 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★).
Frequency
Genomes: 𝑓 0.27 ( 5701 hom., cov: 32)
Exomes 𝑓: 0.25 ( 40286 hom. )
Consequence
TICAM1
NM_182919.4 3_prime_UTR
NM_182919.4 3_prime_UTR
Scores
2
Clinical Significance
Conservation
PhyloP100: 0.648
Genes affected
TICAM1 (HGNC:18348): (TIR domain containing adaptor molecule 1) This gene encodes an adaptor protein containing a Toll/interleukin-1 receptor (TIR) homology domain, which is an intracellular signaling domain that mediates protein-protein interactions between the Toll-like receptors (TLRs) and signal-transduction components. This protein is involved in native immunity against invading pathogens. It specifically interacts with toll-like receptor 3, but not with other TLRs, and this association mediates dsRNA induction of interferon-beta through activation of nuclear factor kappa-B, during an antiviral immune response. Mutations in this gene are associated with encephalopathy, acute, infection-induced. [provided by RefSeq, Jul 2020]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -14 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.97).
BP6
Variant 19-4816148-A-C is Benign according to our data. Variant chr19-4816148-A-C is described in ClinVar as [Benign]. Clinvar id is 2688085.Status of the report is criteria_provided_single_submitter, 1 stars.
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.409 is higher than 0.05.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
TICAM1 | NM_182919.4 | c.*91T>G | 3_prime_UTR_variant | 2/2 | ENST00000248244.6 | ||
TICAM1 | NM_001385678.1 | c.*91T>G | 3_prime_UTR_variant | 3/3 | |||
TICAM1 | NM_001385679.1 | c.*91T>G | 3_prime_UTR_variant | 2/2 | |||
TICAM1 | NM_001385680.1 | c.*91T>G | 3_prime_UTR_variant | 3/3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
TICAM1 | ENST00000248244.6 | c.*91T>G | 3_prime_UTR_variant | 2/2 | 1 | NM_182919.4 | P1 |
Frequencies
GnomAD3 genomes AF: 0.266 AC: 40463AN: 151916Hom.: 5693 Cov.: 32
GnomAD3 genomes
AF:
AC:
40463
AN:
151916
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.251 AC: 310519AN: 1236284Hom.: 40286 Cov.: 30 AF XY: 0.250 AC XY: 149533AN XY: 597454
GnomAD4 exome
AF:
AC:
310519
AN:
1236284
Hom.:
Cov.:
30
AF XY:
AC XY:
149533
AN XY:
597454
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.266 AC: 40505AN: 152034Hom.: 5701 Cov.: 32 AF XY: 0.273 AC XY: 20317AN XY: 74306
GnomAD4 genome
AF:
AC:
40505
AN:
152034
Hom.:
Cov.:
32
AF XY:
AC XY:
20317
AN XY:
74306
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
1159
AN:
3478
ClinVar
Significance: Benign
Submissions summary: Benign:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Benign:1
Benign, criteria provided, single submitter | clinical testing | Unidad de Genómica Garrahan, Hospital de Pediatría Garrahan | Jan 24, 2024 | This variant is classified as Benign based on local population frequency. This variant was detected in 56% of patients studied by a panel of primary immunodeficiencies. Number of patients: 53. Only high quality variants are reported. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at